Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

2024 · doi:10.20944/preprints202401.0670.v1

preprint OA: closed CC-BY-4.0

🔓 Open OA copy View at publisher

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

A Phase III Randomized Controlled Trial Assessing the Safety and Immunogenicity of Biological E’s XBB 1.5 RBD Subunit COVID-19 Booster Vaccine in Individuals Aged 5 to 80 Years 2025

Cited by (1)

A Phase III Randomized Controlled Trial Assessing the Safety and Immunogenicity of Biological E’s XBB 1.5 RBD Subunit COVID-19 Booster Vaccine in Individuals Aged 5 to 80 Years 2025

Source provenance

europepmc: last seen: 2026-05-19T01:45:01.086888+00:00
unpaywall: last seen: 2026-06-02T02:00:03.124865+00:00

License: CC-BY-4.0